

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward: NHI:

Fluticasone furoate with umeclidinium and vilanterol

INITIATION

Prerequisites (tick boxes where appropriate)

Patient has a diagnosis of COPD confirmed by spirometry or spirometry has been attempted and technically acceptable results are not possible
and

Patient is currently receiving an inhaled corticosteroid with long acting beta-2 agonist (ICS/LABA) or a long acting muscarinic antagonist with long acting beta-2 agonist (LAMA/LABA)
and

Clinical criteria:

Patient has a COPD Assessment Test (CAT) score greater than 10
or
 Patient has had 2 or more exacerbations in the previous 12 months
or
 Patient has had one exacerbation requiring hospitalisation in the previous 12 months
or
 Patient has had an eosinophil count greater than or equal to 0.3×10^9 cells/L in the previous 12 months

or

Patient is currently receiving multiple inhaler triple therapy (inhaled corticosteroid with long acting muscarinic antagonist and long acting beta-2 agonist – ICS/LAMA/LABA) and met at least one of the clinical criteria above prior to commencing multiple inhaler triple therapy

I confirm that the above details are correct:

Signed: Date: